Skip to content

Maintenance treatment with slow-released methylphenidate in subjects with methamphetamine dependence: efficacy and side effects

Maintenance treatment with slow-released methylphenidate in subjects with methamphetamine dependence: efficacy and side effects

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003347
Enrollment
Unknown
Registered
2013-05-28
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

methamphetamine dependence

Interventions

group A:methylphenidate SR
group B:Placebo

Sponsors

Ningbo Addiction Research and Treatment Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Subjects will be recruited from inpatient department in Ningbo Addiction and Treatment Center, and meet the following criteria: 1. Treatment-seeking subjects with age between 18 years and 55 years, both genders are eligible for study; 2. Meet the DSM-IV diagnosis of methamphetamine dependence in the latest year; 3. Be willing and able to comply with study procedures, be able to verbalize and understand consent forms and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. currently having neurological disorders including epilepsy, brain tumor, multiple sclerosis, Gilles de la Tourette syndrome, anxiety disorder and psychotic disorders; 2. Diagnosis of Gilles de la Tourette syndrome in the immediate family; 3. Current dependence on substances other than nicotine or amphetamine type stimulants; 4. Having contraindications such as pregnancy, glaucoma, cardiomyopathies and severe arrhythmia; 5. Having conditions that may pre-terminate the trial, such as liver dysfunction, kidney dysfunction, anemia, leucocytopenia, and thrombocytopenia; 6. Other conditions that makes the subjects unlikely to finish the follow-up, e.g., traffic inconvenience.

Design outcomes

Primary

MeasureTime frame
time of abstinence;the reduction of methamphetamine use;

Secondary

MeasureTime frame
retention;Obsessive compulisive drug use scale;desires for drug questionnaire;Pittsburgh sleep quality index;

Countries

China

Contacts

Public ContactWenhua ZHOU
whzhou@vip.163.com+86 574 87145142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026